BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

BridgePoint Medical Receives European CE Mark for Stingray(R) and CrossBoss(TM) for Opening Completely Blocked Arteries


11/23/2009 9:45:25 AM

Bookmark and Share

MINNEAPOLIS, Nov. 23 /PRNewswire/ -- BridgePoint Medical announced today that it received European CE Mark (Conformite Europeene) for its coronary and peripheral Chronic Total Occlusion (CTO) Crossing System comprised of the CrossBoss(TM) CTO Crossing Catheter and the Stingray(R) CTO Re-Entry System. The BridgePoint System is a series of interventional catheters that are designed to navigate highly diseased arteries in preparation for blood flow restoration via angioplasty and stenting.

"We have seen many attempts to implement new tools for the treatment of chronic coronary occlusions over the years, but until now none of them have provided any advantage over the current treatment of using specialty guidewires," said Gerald Werner M.D. Ph.D., Professor at the Klinikum Darmstadt in Darmstadt, Germany. "This system is the first to provide a new option for the frequent situation when our guidewires do not reach the vessel beyond the occlusion. The BridgePoint system makes it possible to find the true vessel lumen and conclude the treatment successfully."

"The CrossBoss and Stingray devices provide interventionalists in the E.U. with new opportunities to treat patients with highly diseased arteries. We believe that these devices represent an important new advance in interventional cardiology," said Chad Kugler, Co-Founder, President and General Manager, BridgePoint Medical. "This technology exemplifies BridgePoint's innovative approach to CTO treatment and our commitment to further reduce the need for invasive bypass surgery."

Clinical Trial Summary

In a prospective clinical trial conducted in the European Union and a post-market registry conducted primarily in South America the BridgePoint System was 67%-85% successful in placing an interventional guidewire beyond a chronic total coronary occlusion. Complications with the system were similar to general PCI and stenting.

About Chronic Total Coronary Occlusions

The National Heart, Lung and Blood Institute (NHLBI) estimates that Chronic Total Occlusions (CTOs) are common and are found in approximately one-third of patients who undergo angiography. Patients surviving with a CTO commonly suffer from poor blood circulation to the heart muscle that induces symptoms such as chest pain (angina), shortness of breath and fatigue. Studies also show that the patients living with an untreated coronary CTO are at higher risk of death.

BridgePoint Medical, Inc.




Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES